|
GB8804188D0
(en)
*
|
1988-02-23 |
1988-03-23 |
Croda Int Plc |
Pharmaceutical compositions
|
|
US5407957A
(en)
*
|
1990-02-13 |
1995-04-18 |
Martek Corporation |
Production of docosahexaenoic acid by dinoflagellates
|
|
ES2059880T3
(es)
*
|
1990-05-23 |
1994-11-16 |
Nestle Sa |
Utilizacion del acido estearidonico para el tratamiento de las enfermedades inflamatorias.
|
|
GB9012651D0
(en)
*
|
1990-06-06 |
1990-07-25 |
Efamol Holdings |
Essential fatty acid treatment
|
|
WO1992012711A1
(en)
*
|
1991-01-24 |
1992-08-06 |
Martek Corporation |
Microbial oil mixtures and uses thereof
|
|
CA2151820C
(en)
*
|
1993-01-15 |
2000-11-28 |
Stephen Joseph Demichele |
Structured lipids
|
|
US20050027004A1
(en)
*
|
1993-06-09 |
2005-02-03 |
Martek Biosciences Corporation |
Methods of treating senile dementia and Alzheimer's diseases using docosahexaenoic acid and arachidonic acid compositions
|
|
US5411988A
(en)
*
|
1993-10-27 |
1995-05-02 |
Bockow; Barry I. |
Compositions and methods for inhibiting inflammation and adhesion formation
|
|
US5840715A
(en)
*
|
1995-12-11 |
1998-11-24 |
Inholtra Investment Holdings & Trading, N.V. |
Dietary regimen of nutritional supplements for relief of symptoms of arthritis
|
|
CA2240165A1
(en)
*
|
1995-12-11 |
1997-06-19 |
Inholtra, Inc. |
Dietary regimen of nutritional supplements for relief of symptoms of arthritis
|
|
DE19629433A1
(de)
*
|
1996-07-22 |
1998-01-29 |
Hoechst Ag |
Omega-3-fettsäurenenthaltende Zubereitung aus Mikroorganismen als Prophylaktikum bzw. Therapeutikum gegen parasitäre Erkrankungen beim Tier
|
|
US6051754A
(en)
*
|
1997-04-11 |
2000-04-18 |
Abbott Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
|
|
US6075183A
(en)
*
|
1997-04-11 |
2000-06-13 |
Abbott Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids in plants
|
|
US5968809A
(en)
*
|
1997-04-11 |
1999-10-19 |
Abbot Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
|
|
US7745694B1
(en)
|
1997-04-11 |
2010-06-29 |
Monsanto Technology Llc |
Methods and compositions for synthesis of long chain polyunsaturated fatty acids in plants
|
|
US5972664A
(en)
*
|
1997-04-11 |
1999-10-26 |
Abbott Laboratories |
Methods and compositions for synthesis of long chain poly-unsaturated fatty acids
|
|
US6180671B1
(en)
*
|
1998-03-10 |
2001-01-30 |
Beth Israel Deaconess Medical Center, Inc. |
Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected
|
|
US6136795A
(en)
*
|
1998-11-18 |
2000-10-24 |
Omni Nutraceuticals, Inc |
Dietary regimen of nutritional supplements for relief of symptoms of arthritis
|
|
GB9901809D0
(en)
|
1999-01-27 |
1999-03-17 |
Scarista Limited |
Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
|
|
US6395778B1
(en)
|
2000-01-11 |
2002-05-28 |
Omegatech, Inc. |
Process for making an enriched mixture of polyunsaturated fatty acid esters
|
|
US20040241249A1
(en)
*
|
2001-06-18 |
2004-12-02 |
Tina Sampalis |
Krill and/or marine extracts for prevention and/or treatment of cardiovascular diseases arthritis, skin cancer diabetes, premenstrual syndrome and transdermal transport
|
|
WO2004091603A1
(fr)
*
|
2003-04-07 |
2004-10-28 |
Clinigenetics |
Utilisation d’un ester de dha pour le traitement des malades cardiovasculaires
|
|
US8633246B2
(en)
*
|
2003-08-11 |
2014-01-21 |
Hill's Pet Nutrition, Inc. |
Omega-3 fatty acids for osteoarthritis
|
|
US8633247B2
(en)
|
2003-08-11 |
2014-01-21 |
Hill's Pet Nutrition, Inc. |
Method for decreasing cartilage damage in dogs
|
|
US8075910B2
(en)
*
|
2004-05-20 |
2011-12-13 |
Pbm Pharmaceuticals, Inc. |
Oral compositions comprising edible oils and vitamins and/or minerals and methods for making oral compositions
|
|
PL1833498T3
(pl)
*
|
2004-11-29 |
2010-06-30 |
Unilever Nv |
Doustna kompozycja do polepszania właściwości skóry
|
|
US20060286199A1
(en)
*
|
2005-06-03 |
2006-12-21 |
Marilou Laprise |
Method and composition for increasing omega-3 lipid in milk
|
|
WO2007116027A1
(en)
*
|
2006-04-12 |
2007-10-18 |
Unilever Plc |
Oral composition comprising a polyunsaturated fatty acid and salicylic acid for obtaining an antiinflammatory effect in skin
|
|
JP2009534317A
(ja)
*
|
2006-04-12 |
2009-09-24 |
ユニリーバー・ナームローゼ・ベンノートシヤープ |
皮膚に対する抗老化効果を有する経口組成物
|
|
US20080058418A1
(en)
*
|
2006-09-06 |
2008-03-06 |
The Coca-Cola Company |
Stable polyunsaturated fatty acid emulsions and methods for inhibiting, suppressing, or reducing degradation of polyunsaturated fatty acids in an emulsion
|
|
US20090018186A1
(en)
*
|
2006-09-06 |
2009-01-15 |
The Coca-Cola Company |
Stable beverage products comprising polyunsaturated fatty acid emulsions
|
|
DE102007055344A1
(de)
*
|
2007-11-19 |
2009-05-20 |
K. D. Pharma Bexbach Gmbh |
Neue Verwendung von Omega-3-Fettsäure(n)
|
|
EP3187182B1
(de)
|
2008-09-02 |
2021-03-03 |
Amarin Pharmaceuticals Ireland Limited |
Pharmazeutische zusammensetzungen mit eicosapentaensäure und nikotinsäure und verfahren zur verwendung davon
|
|
RU2505292C2
(ru)
|
2009-02-10 |
2014-01-27 |
Амарин Фармасьютикалз Айрлэнд Лимитед |
Способы лечения гипертриглицеридемии
|
|
CN102421422A
(zh)
*
|
2009-03-09 |
2012-04-18 |
普罗诺瓦生物医药挪威公司 |
含有脂肪酸油混合物和表面活性剂的组合物及其方法和用途
|
|
CN102438468B
(zh)
|
2009-04-17 |
2014-06-04 |
纳塔克制药有限公司 |
富含低含量植烷酸的ω-3脂肪酸的组合物
|
|
CN107233337A
(zh)
|
2009-04-29 |
2017-10-10 |
阿马里纳药物爱尔兰有限公司 |
含有epa和心血管剂的药物组合物以及使用其的方法
|
|
MX377553B
(es)
|
2009-04-29 |
2025-03-10 |
Amarin Pharma Inc |
Composicion farmaceutica estable y metodos de uso de la misma.
|
|
BRPI1011883A2
(pt)
|
2009-06-15 |
2016-09-13 |
Amarin Pharma Inc |
uso de composições para redução de triglicerídeos sem elevar os níveis de o ldl-c em um paciente sob o tratamento concomitante com estatina
|
|
NZ599061A
(en)
|
2009-09-23 |
2014-05-30 |
Amarin Pharmaceuticals Ie Ltd |
Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same
|
|
KR101204748B1
(ko)
*
|
2009-12-17 |
2012-11-26 |
(주) 켐포트 |
고도 불포화 지방산을 고농도로 함유하는 트리글리세라이드 유지의 제조방법
|
|
WO2011097276A1
(en)
*
|
2010-02-02 |
2011-08-11 |
Martek Biosciences Corporation |
Methods and compositions for treating arthritis with docosahexaenoic acid
|
|
KR20130139896A
(ko)
*
|
2010-09-08 |
2013-12-23 |
프로노바 바이오파마 너지 에이에스 |
유리산 형태의 epa 및 dha, 계면활성제, 및 스타틴을 포함하는 조성물
|
|
NZ744990A
(en)
|
2010-11-29 |
2019-10-25 |
Amarin Pharmaceuticals Ie Ltd |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
US11712429B2
(en)
|
2010-11-29 |
2023-08-01 |
Amarin Pharmaceuticals Ireland Limited |
Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity
|
|
WO2013070735A1
(en)
|
2011-11-07 |
2013-05-16 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
US11291643B2
(en)
|
2011-11-07 |
2022-04-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating hypertriglyceridemia
|
|
CN107050457A
(zh)
|
2012-01-06 |
2017-08-18 |
翁特拉制药公司 |
游离酸形式的ω‑3多不饱和脂肪酸的富含dpa组合物
|
|
EP2800469B1
(de)
|
2012-01-06 |
2021-08-25 |
Amarin Pharmaceuticals Ireland Limited |
Zusammensetzungen und verfahren zur senkung der konzentration an hochsensitivem c-reaktiven protein (hs-crp) bei einer person
|
|
KR20150028233A
(ko)
|
2012-05-07 |
2015-03-13 |
옴테라 파마슈티칼스, 인크. |
스타틴 및 오메가-3 지방산의 조성물
|
|
US9603826B2
(en)
|
2012-06-29 |
2017-03-28 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of a cardiovascular event in a subject on statin therapy
|
|
WO2014074552A2
(en)
|
2012-11-06 |
2014-05-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy
|
|
US20140187633A1
(en)
|
2012-12-31 |
2014-07-03 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis
|
|
US9814733B2
(en)
|
2012-12-31 |
2017-11-14 |
A,arin Pharmaceuticals Ireland Limited |
Compositions comprising EPA and obeticholic acid and methods of use thereof
|
|
US9452151B2
(en)
|
2013-02-06 |
2016-09-27 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing apolipoprotein C-III
|
|
US9624492B2
(en)
|
2013-02-13 |
2017-04-18 |
Amarin Pharmaceuticals Ireland Limited |
Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
|
|
US9662307B2
(en)
|
2013-02-19 |
2017-05-30 |
The Regents Of The University Of Colorado |
Compositions comprising eicosapentaenoic acid and a hydroxyl compound and methods of use thereof
|
|
US9283201B2
(en)
|
2013-03-14 |
2016-03-15 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for treating or preventing obesity in a subject in need thereof
|
|
US20140271841A1
(en)
|
2013-03-15 |
2014-09-18 |
Amarin Pharmaceuticals Ireland Limited |
Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin
|
|
US10966968B2
(en)
|
2013-06-06 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof
|
|
US20150065572A1
(en)
|
2013-09-04 |
2015-03-05 |
Amarin Pharmaceuticals Ireland Limited |
Methods of treating or preventing prostate cancer
|
|
US9585859B2
(en)
|
2013-10-10 |
2017-03-07 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy
|
|
US10561631B2
(en)
|
2014-06-11 |
2020-02-18 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing RLP-C
|
|
WO2015195662A1
(en)
|
2014-06-16 |
2015-12-23 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids
|
|
US10406130B2
(en)
|
2016-03-15 |
2019-09-10 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids
|
|
US10966951B2
(en)
|
2017-05-19 |
2021-04-06 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject having reduced kidney function
|
|
US11058661B2
(en)
|
2018-03-02 |
2021-07-13 |
Amarin Pharmaceuticals Ireland Limited |
Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L
|
|
MA50490A
(fr)
|
2018-09-24 |
2020-09-02 |
Amarin Pharmaceuticals Ie Ltd |
Procédés de réduction du risque d'événements cardiovasculaires chez un sujet
|
|
CA3160676A1
(en)
|
2019-11-12 |
2021-05-20 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of cardiovascular events in a subject with atrial fibrillation and/or atrial flutter
|
|
US11986452B2
(en)
|
2021-04-21 |
2024-05-21 |
Amarin Pharmaceuticals Ireland Limited |
Methods of reducing the risk of heart failure
|